Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy

Journal of Virology

Volumn 74, Issue 9, 2000, Pages 4017-4027

  Mooij, Petra ^a   Bogers, Willy M J M ^a   Oostermeijer, Herman ^a   Koornstra, Wim ^a   Ten Haaft, Peter J F ^a   Verstrepen, Babs E ^a   Van Der Auwera, Gert ^b   Heeney, Jonathan L ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LYMPHOCYTE COUNT; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; STRAIN DIFFERENCE; TREATMENT FAILURE; VACCINATION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS STRAIN; VIRUS VIRULENCE;

AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, ATTENUATED; VIRULENCE;

EID: 0033995282     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.9.4017-4027.2000     Document Type: Article

References (66)

1. Abimiku, A. G., G. Franchini, J. Tartaglia, K. Aldrich, M. Myagkikh, P. D. Markham, P. Chong, M. Klein, M. P. Kieny, E. Paoletti, et al. 1995. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat. Med. 1:321-329.
2. Almond, N. M., and J. L. Heeney. 1998. AIDS vaccine development in primate models. AIDS 12:S133-S140.
3. Anonymous. 1994. HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. WHO Network for HIV Isolation and Characterization. AIDS Res. Hum. Retroviruses 10:1327-1343.
4. Baba, T. W., Y. S. Jeong, D. Pennick, R. Bronson, M. F. Greene, and R. M. Ruprecht. 1995. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820-1825.
5. Baba, T. W., V. Liska, A. H. Khimani, N. B. Ray, P. J. Dailey, D. Penninck, R. Bronson, M. F. Green, H. M. McClure, L. N. Martin, and R. M. Ruprecht. 1999. Live attenuated, multiple deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5:194-203.
6. Bloom, B. R. 1996. A perspective on AIDS vaccines. Science 272:1888-1890.
7. Bogers, W. M., R. Dubbes, P. ten Haaft, H. Niphuis, C. Cheng-Mayer, C. Stahl-Hennig, G. Hunsmann, T. Kuwata, M. Hayami, S. Jones, S. Ranjbar, N. Almond, J. Stott, B. Rosenwirth, and J. L. Heeney. 1997. Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta. Virology 236: 110-117.
8. Bogers, W. M., W. H. Koornstra, R. H. Dubbes, P. J. ten Haaft, B. E. Verstrepen, S. S. Jhagjhoorsingh, A. G. Haaksma, H. Niphuis, J. D. Laman, S. Norley, H. Schuitemaker, J. Goudsmit, G. Hunsmann, J. L. Heeney, and H. Wigzell. 1998. Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees. J. Gen. Virol. 79:2895-2903.
9. Bogers, W. M., H. Niphuis, P. ten-Haaft, J. D. Laman, W. Koornstra, and J. L. Heeney. 1995. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. AIDS 9:F13-F18.
10. Bou-Habib, D. C., G. Roderiquez, T. Oravecz, P. W. Berman, P. Lusso, and M. A. Norcross. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006-6013.
11. Bruck, C., C. Thiriart, L. Fabry, M. Francotte, P. Pala, O. Van-Opstal, J. Culp, M. Rosenberg, M. De-Wilde, P. Heidt, and J. L. Heeney. 1994. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 12:1141-1148.
12. Burton, D. R., and J. P. Moore. 1998. Why do we not have an HIV vaccine and how can we make one? Nat. Med. 4:495-498.
13. Cafaro, A., A. Caputo, C. Fracasso, M. T. Maggiorella, D. Goletti, S. Baroncelli, M. Pace, L. Sernicola, M. L. Koanga-Mogtomo, M. Betti, A. Borsetti, R. Belli, L. Akerblom, F. Corrias, S. Butto, J. Heeney, P. Verani, F. Titti, and B. Ensoli. 1999. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med. 5:643-650.
14. Cheng-Mayer, C., T. Shioda, and J. A. Levy. 1991. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120. J. Virol. 65:6931-6941.
15. Collman, R., J. W. Balliet, S. A. Gregory, H. Friedman, D. L. Kolson, N. Nathanson, and A. Srinivasan. 1992. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66:7517-7521.
16. Connor, R. I., B. T. Korber, B. S. Graham, B. H. Hahn, D. D. Ho, B. D. Walker, A. U. Neumann, S. H. Vermund, J. Mestecky, S. Jackson, E. Fenamore, Y. Cao, F. Gao, S. Kalams, K. J. Kunstman, D. McDonald, N. McWilliams, A. Trkola, J. P. Moore, and S. M. Wolinsky. 1998. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol. 72:1552-1576.
17. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941.
18. Dittmer, U., D. M. Brooks, and K. J. Hasenkrug. 1999. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat. Med. 5:189-193.
19. Dunn, C. S., B. Hurtrel, C. Beyer, L. Gloeckler, T. N. Ledger, C. Moog, M. P. Kieny, M. Mehtali, D. Schmitt, J. P. Gut, A. Kirn, and A. M. Aubertin. 1997. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1. AIDS Res. Hum. Retroviruses 13:913-922.
20. Esparza, J., W. L. Heyward, and S. Osmanov. 1996. HIV vaccine development: from basic research to human trials. AIDS 10:S123-S132.
21. Gibbs, C. J., Jr., R. Peters, M. Gravell, B. K. Johnson, F. C. Jensen, D. J. Carlo, and J. Salk. 1991. Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees. Proc. Natl. Acad. Sci. USA 88:3348-3352.
22. Glantz, S. A. 1989. Primer of biostatistics, p. 64-325. In B. Kaufman, B. White, and J. White (ed.), Medical statistics series, 2nd ed., vol. 1. McGraw-Hill International Editions, Singapore, Republic of Singapore.
23. Groenink, M., A. C. Andeweg, R. A. Fouchier, S. Broersen, R. C. van-der-Jagt, H. Schuitemaker, R. E. de-Goede, M. L. Bosch, H. G. Huisman, and M. Tersmette. 1992. Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J. Virol. 66:6175-6180.
24. Groenink, M., R. A. Fouchier, R. E. de-Goede, F. de-Wolf, R. A. Gruters, H. T. Cuypers, H. G. Huisman, and M. Tersmette. 1991. Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J. Virol. 65:1968-1975.
25. Heeney, J., L. Akerblom, S. Barnett, W. Bogers, D. Davis, D. Fuller, G. Koopman, T. Lehner, P. Mooij, B. Morein, C. de Giuli Morghen, B. Rosenwirth, E. Verschoor, R. Wagner, and H. Wolf. 1999. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol. Lett. 66:189-195.
26. Heeney, J. L., P. Beverley, A. McMichael, G. Shearer, J. Strominger, B. Wahren, J. Weber, and F. Gotch. 1999. Immune correlates of protection from HIV and AIDS - more answers but yet more questions. Immunol. Today 20:247-251.
27. Heeney, J. L., C. Bruck, J. Goudsmit, L. Montagnier, A. Schultz, D. Tyrrell, and S. Zolla-Pazner. 1997. Immune correlates of protection from HIV infection and AIDS. Immunol. Today 18:4-8.
28. Heeney, J. L., L. Holterman, P. ten Haaft, R. Dubbes, W. Koornstra, V. Teeuwsen, P. Bourquin, S. Norley, and H. Niphuis. 1994. Vaccine protection and reduced virus load from heterologous macaque propagated SIV challenge. AIDS Res. Hum. Retroviruses 10:S117-S121.
29. Heeney, J. L., P. Mooij, W. Bogers, D. Davis, B. Morein, C. de Giuli Morghen, T. Lehner, G. Voss, C. Bruck, G. Koopman, and B. Rosenwirth. 1998. Multiple immune effector mechanisms as correlates of HIV-1 vaccine protection, p. 281-285. In M. Girard and B. Dodet (ed.), Retroviruses of human AIDS and related animal diseases. 11th ed. Eisevier, Paris, France.
30. Heeney, J. L., V. J. Teeuwsen, M. van Gils, W. M. Bogers, C. De Giuli Morghen, A. Radaelli, S. Barnett, B. Morein, L. Akerblom, Y. Wang, T. Lehner, and D. Davis. 1998. Beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc. Natl. Acad. Sci. USA 95:10803-10808.
31. + T cells and AIDS in pig-tailed macaques. J. Virol. 70:3189-3197.
32. + lymphocyte depletion in rhesus monkeys. J. Virol. 71:4218-4225.
33. Kuwata, T., T. Igarashi, E. Ido, M. Jin, A. Mizuno, J. Chen, and M. Hayami. 1995. Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication. J. Gen. Virol. 76:2181-2191.
34. Kuwata, T., T. Shioda, T. Igarashi, E. Ido, K. Ibuki, Y. Enose, C. Stahl-Hennig, G. Hunsmann, T. Miura, and M. Hayami. 1996. Chimeric viruses between SIVmac and various HIV-1 isolates have biological properties that are similar to those of the parental HIV-1. AIDS 10:1331-1337.
35. LaCasse, R. A., K. E. Follis, M. Trahey, J. D. Scarborough, D. R. Littman, and J. H. Nunberg. 1999. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 283:357-362.
36. Langlois, A. J., R. C. Desrosiers, M. G. Lewis, V. N. KewalRamani, D. R. Littman, J. Y. Zhou, K. Manson, M. S. Wyand, D. P. Bolognesi, and D. C. Montefiori. 1998. Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. J. Virol. 72:6950-6955.
37. Letvin, N. L., and N. W. King. 1990. Immunologic and pathologic manifestations of infection of rhesus monkeys with simian immunodeficiency virus of macaques. J. Acquir. Immune Defic. Syndr. 3:1023-1040.
38. Lewis, M. G., J. Yalley-Ogunro, J. J. Greenhouse, T. P. Brennan, J. B. Jiang, T. C. VanCott, Y. Lu, G. A. Eddy, and D. L. Birx. 1999. Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus. J. Virol. 73:1262-1270.
39. Li, J., C. I. Lord, W. Haseltine, N. L. Letvin, and J. Sodroski. 1992. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J. Acquir. Immune Defic. Syndr. 5:639-646.
40. Lu, Y., C. D. Pauza, X. Lu, D. C. Montefiori, and C. J. Miller. 1998. Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J. Acquir. Immune Defic. Syndr. Hum. Retroviral. 19:6-18.
41. Luciw, P. A., E. Pratt-Lowe, K. E. Shaw, J. A. Levy, and C. Cheng-Mayer. 1995. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc. Natl. Acad. Sci. USA 92:7490-7494.
42. Marthas, M. L., S. Sutjipto, J. Higgins, B. Lohman, J. Torten, P. A. Luciw, P. A. Marx, and N. C. Pedersen. 1990. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J. Virol. 64:3694-3700.
43. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCutchan, and D. S. Burke. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173:340-348.
44. Merson, M. H. 1993. Slowing the spread of HIV: agenda for the 1990s. Science 260:1266-1268.
45. Mooij, P., M. van der Kolk, W. M. Bogers, P. J. ten Haaft, P. Van Der Meide, N. Almond, J. Stott, M. Deschamps, D. Labbe, P. Momin, G. Voss, P. Von Hoegen, C. Bruck, and J. L. Heeney. 1998. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS 12:F15-F22.
46. Moore, J. P., Y. Cao, L. Qing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas III, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
47. Murthy, K. K., E. K. Cobb, Z. el-Amad, H. Ortega, F. C. Hsueh, W. Satterfield, D. R. Lee, M. L. Kalish, N. L. Haigwood, R. C. Kennedy, K. S. Steimer, A. Schultz, and J. A. Levy. 1996. Titration of a vaccine stock preparation of human immunodeficiency virus type 1SF2 in cultured lymphocytes and in chimpanzees. AIDS Res. Hum. Retroviruses 12:1341-1348.
48. Myers, G, B. Korber, S. Wain-Hobson, K.-T. Jeang, L. E. Henderson, and G. N. Pavlakis. 1994. Human retroviruses and AIDS database. Los Alamos National Laboratory, Los Alamos, N.Mex.
49. Osmanov, S., W. L. Heyward, and J. Esparza. 1994. The World Health Organization Network for HIV Isolation and Characterization: summary of a pilot study. AIDS Res. Hum. Retroviruses 10:1325-1326.
50. Ranjbar, S., S. Jones, E. J. Stott, and N. Almond. 1997. The construction and evaluation of SIV/HIV chimeras that express the envelope of European HIV type 1 isolates. AIDS Res. Hum. Retroviruses 13:797-800.
51. Reimann, K., J. T. Li, R. Veazey, M. Halloran, I. Park, G. B. Karlsson, J. Sodroski, and N. L. Letvin. 1996. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70:6922-6928.
52. Reimann, K. A., J. T. Li, G. Voss, C. Lekutis, K. Tenner-Racz, P. Racz, W. Lin, D. C. Montefiori, D. E. Lee-Parritz, Y. Lu, R. G. Collman, J. Sodroski, and N. L. Letvin. 1996. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J. Virol. 70:3198-3206.
53. Robinson, H. L., D. C. Montefiori, R. P. Johnson, K. H. Manson, M. L. Kalish, J. D. Lifson, T. A. Rizvi, S. Lu, S. L. Hu, G. P. Mazzara, D. L. Panicali, J. G. Herndon, R. Glickman, M. A. Candido, S. L. Lydy, M. S. Wyand, and H. M. McClure. 1999. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5:526-534.
54. Sauermann, U., J. Schneider, J. Mous, U. Brunckhorst, I. Schedel, K. D. Jentsch, and G. Hunsmann. 1990. Molecular cloning and characterization of a German HIV-1 isolate. AIDS Res. Hum. Retroviruses 6:813-823.
55. Stott, E. J., N. Almond, K. Kent, B. Walker, R. Hull, J. Rose, P. Silvera, R. Sangster, T. Corcoran, J. Lines, K. Silvera. P. Luciw, M. Murphy-Corb, P. Momin, and C. Bruck. 1998. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. J Gen. Virol. 79:423-432.
56. Stoute, J. A., M. Slaoui, D. G. Heppner, P. Momin, K. E. Kester, P. Desmons, B. T. Wellde, N. Garcon, U. Kryzch, M. Marchand, W. R. Ballou, and J. D. Cohen. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336:86-91.
57. Ten Haaft, P., B. Verstrepen, K. Uberla, B. Rosenwirth, and J. Heeney. 1998. A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J. Virol. 72:10281-10285.
58. Titti, F., L. Sernicola, A. Geraci, G. Panzini, S. Di Fabio, R. Belli, F. Monardo, A. Borsetti, M. T. Maggiorella, M. Koanga-Mogtomo, F. Corrias, R. Zamarchi, A. Amadori, L. Chieco-Bianchi, and P. Verani. 1997. Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J. Gen. Virol. 78:2529-2539.
59. Travers, K., S. Mboup, R. Marlink, A. Gueye-Nidaye, T. Siby, I. Thior, I. Traore, A. Dieng-Sarr, J. L. Sankale, C. Mullins, et al. 1995 Natural protection against HIV-1 infection provided by HIV-2. Science 268:1612-1615.
60. Trkola, A., T. Dragic, J. Arthos, J. M. Binley, W. C. Olson, G. P. Allaway, C. Cheng-Mayer, J. Robinson, P. J. Maddon, and J. P. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187.
61. Vancott, T. C., V. R. Polonis, L. D. Loomis, N. L. Michael, P. L. Nara, and D. L. Birx. 1995. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses 11:1379-1391.
62. Van de Peer, Y., and R. De Wachter. 1994. TREECON for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput. Appl. Biosci. 10:569-570.
63. Verschoor, E. J., P. Mooij, H. Oostermeijer, M. van der Kolk, P. ten Haaft, B. Verstrepen, Y. Sun, B. Morein, L. Akerblom, D. H. Fuller, S. W. Barnett, and J. L. Heeney. 1999. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in rhesus macaques: evidence for viral clearance. J. Virol. 73:3292-3300.
64. von Dalnok, G. K., A. Kleinschmidt, M. Neumann, C. Leib-Moesch, V. Erfle, and R. Brack-Werner. 1993. Productive expression state confers resistance of human immunodeficiency virus (HIV)-2-infected lymphoma cells against superinfection by HIV-1. Arch. Virol. 131:419-429.
65. Weber, J., E. Fenyo, S. Beddows, P. Kaleebu, and A. Bjorndal. 1996. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. J. Virol. 70:7827-7832.
66. Whatmore, A. M., N. Cook, G. A. Hall, S. Sharpe, E. W. Rud, and M. P. Cranage. 1995. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J. Virol. 69:5117-5123.